Publicaciones en las que colabora con Juan Cruz De La Cámara Gómez (10)

2023

  1. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

2022

  1. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

    PLoS ONE, Vol. 17, Núm. 6 June

  2. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214

2021

  1. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  2. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

  2. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

2019

  1. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889

2018

  1. Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii225

2017

  1. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

    Journal of Cancer Research and Therapeutics, Vol. 13, Núm. 2, pp. 240-245